We investigated the effect of miR-30 family members on response to doxorubicin, an anthracycline-based chemotherapy, in multiple human breast cancer cell lines: HCC1937, MDA-MB-361, MCF7, and on response to lapatinib, a dual inhibitor of HER2, in HER2-positive HCC1954. This evidence concerns the gene ERBB2 and breast carcinoma.